Cargando…

Hymeglusin Enhances the Pro-Apoptotic Effects of Venetoclax in Acute Myeloid Leukemia

Venetoclax is used for the priority treatment of elderly patients with acute myeloid leukemia (AML). Resistance or intolerance to venetoclax offsets its clinical benefits in some patients. Combination strategies with other drugs are promising alternatives to overcome the current complications associ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Cheng, Wang, Zhiqin, Yang, Shuanghui, Li, Huan, Zhao, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9277771/ https://www.ncbi.nlm.nih.gov/pubmed/35847946 http://dx.doi.org/10.3389/fonc.2022.864430

Ejemplares similares

Venetoclax plus cyclophosphamide and cytarabine as induction regimen for adult acute myeloid leukemia
por: Zhang, Baohang, et al.
Publicado: (2023)

Venetoclax-Based Combinations in Acute Myeloid Leukemia: Current Evidence and Future Directions
por: Samra, Bachar, et al.
Publicado: (2020)

Real-life monocentric experience of venetoclax-based regimens for acute myeloid leukemia
por: Sciumè, Mariarita, et al.
Publicado: (2023)

Combination of Venetoclax and Midostaurin Efficiently Suppressed Relapsed t(8;21)Acute Myeloid Leukemia With Mutant KIT After Failure of Venetoclax Plus Azacitidine Treatment
por: Li, Zheng, et al.
Publicado: (2022)

Combined venetoclax and alvocidib in acute myeloid leukemia
por: Bogenberger, James, et al.
Publicado: (2017)

Venetoclax-containing regimens in acute myeloid leukemia
por: Aldoss, Ibrahim, et al.
Publicado: (2021)

The successful combination of grapefruit juice and venetoclax in an unfit acute myeloid leukemia patient with adverse risk: A case report
por: Long, Zhangbiao, et al.
Publicado: (2022)

Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022)

Outcomes of Adults With Relapsed/Refractory Acute Myeloid Leukemia Treated With Venetoclax Plus Hypomethylating Agents at a Comprehensive Cancer Center
por: Tenold, Matthew E., et al.
Publicado: (2021)

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia
por: Saliba, Antoine N., et al.
Publicado: (2021)

P438: INTRACELLULAR CITRATE LEVELS MODULATE ANTI-APOPTOTIC PROTEINS TO ENHANCE VENETOCLAX SENSITIVITY IN ACUTE MYELOID LEUKEMIA STEM CELLS
por: Demir, Aykut, et al.
Publicado: (2023)

Targeting Acute Myeloid Leukemia with Venetoclax; Biomarkers for Sensitivity and Rationale for Venetoclax-Based Combination Therapies
por: Griffioen, Mila S., et al.
Publicado: (2022)

Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study
por: Mustafa Ali, Moaath K., et al.
Publicado: (2022)

Venetoclax with Decitabine or Azacitidine in Relapsed or Refractory Acute Myeloid Leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Synergistic efficacy of homoharringtonine and venetoclax on acute myeloid leukemia cells and the underlying mechanisms
por: Yuan, Fangfang, et al.
Publicado: (2022)

In Vitro Sensitivity to Venetoclax and Microenvironment Protection in Hairy Cell Leukemia
por: Vereertbrugghen, Alexia, et al.
Publicado: (2021)

Treatment of Central Nervous System Relapse in Acute Promyelocytic Leukemia by Venetoclax: A Case Report
por: Zhang, Xuzhao, et al.
Publicado: (2021)

Evaluating venetoclax and its potential in treatment-naïve acute myeloid leukemia
por: Knight, Tristan, et al.
Publicado: (2019)

How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia
por: Maiti, Abhishek, et al.
Publicado: (2022)

Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia: Are Supporting Evidences Enough?
por: Brancati, Serena, et al.
Publicado: (2021)

Radical surgery and venetoclax plus azacitidine in an octogenarian with acute myeloid leukemia
por: Ramdohr, Florian, et al.
Publicado: (2022)

Pharmacokinetics of Venetoclax Co-Administered with Posaconazole in Patients with Acute Myeloid Leukemia
por: De Gregori, Simona, et al.
Publicado: (2023)

Venetoclax with decitabine or azacitidine in the first‐line treatment of acute myeloid leukemia
por: Bouligny, Ian M., et al.
Publicado: (2023)

Building on Foundations: Venetoclax-Based Combinations in the Treatment of Acute Myeloid Leukemia
por: Oyogoa, Emmanuella, et al.
Publicado: (2023)

Practical Management of the Venetoclax-Treated Patient in Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia
por: Waggoner, Matthew, et al.
Publicado: (2022)

S123: ACUTE MYELOID LEUKEMIA STEM CELL SUBTYPES DEFINED BY MUTATIONS AND DIFFERENTIATION STATE REGULATE APOPTOTIC DEPENDENCY AND CLINICAL RESPONSE TO VENETOCLAX.
por: Waclawiczek, Alexander, et al.
Publicado: (2023)

Synergistic effect of chidamide and venetoclax on apoptosis in acute myeloid leukemia cells and its mechanism
por: Li, Gangping, et al.
Publicado: (2021)

Venetoclax and Azacitidine in Chinese patients with untreated acute myeloid leukemia ineligible for intensive chemotherapy
por: Xia, Leiming, et al.
Publicado: (2023)

Targeting Bcl-2 Proteins in Acute Myeloid Leukemia
por: Wei, Yunxiong, et al.
Publicado: (2020)

Ceramide nanoliposomes augment the efficacy of venetoclax and cytarabine in models of acute myeloid leukemia
por: Khokhlatchev, Andrei V., et al.
Publicado: (2022)

PB1840: MONOCENTRIC EXPERIENCE OF VENETOCLAX-BASED REGIMENS FOR ACUTE MYELOID LEUKEMIA
por: Sciumè, M., et al.
Publicado: (2022)

An integrative systems biology approach to overcome venetoclax resistance in acute myeloid leukemia
por: Przedborski, Michelle, et al.
Publicado: (2022)

Venetoclax response prediction in acute myeloid leukemia: are we Finnish-ed with uncertainty?
por: Stevens, Brett, et al.
Publicado: (2023)

Venetoclax Overcomes Sorafenib Resistance in Acute Myeloid Leukemia by Targeting BCL2
por: Xu, Xi, et al.
Publicado: (2023)

P476: AN ORAL COMBINATION THERAPY OF OR-2100 AND VENETOCLAX IN ACUTE MYELOID LEUKEMIA
por: Kamachi, Kazuharu, et al.
Publicado: (2023)

Venetoclax and Decitabine for T/Myeloid Mixed-Phenotype Acute Leukemia Not Otherwise Specified (MPAL NOS)
por: Klocke, Heather, et al.
Publicado: (2020)

Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
por: Tahir, Stephen K., et al.
Publicado: (2023)

A novel cuproptosis-related LncRNA signature: Prognostic and therapeutic value for acute myeloid leukemia
por: Li, Pian, et al.
Publicado: (2022)

Metformin exerts a synergistic effect with venetoclax by downregulating Mcl-1 protein in acute myeloid leukemia
por: Zhou, Fang-jiao, et al.
Publicado: (2021)

Murine Models of Acute Myeloid Leukemia
por: Kurtz, Kristen J., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_u54f164p59vdt5nkdq204gv2oc